Table 1 Clinicopathological characteristics of melanoma patients and tumors and relation with HOXC13 expression

Sex N°

Male

1 (4,5%)

13 (59,1%)

7 (31,8%)

1 (4,5%)

48

0,945

Female

2 (7,7%)

16 (61,5%)

8 (30,8%)

0 (0%)

Clark level

I

0 (0%)

2 (100,0%)

0 (0%)

0 (0%)

II

0 (0%)

10 (62,5%)

6 (37,5%)

0 (0%)

48

0,1111

III

3 (12,0%)

13 (52,0%)

9 (36,0%)

0 (0%)

IV

0 (0%)

4 (80,0%)

0 (0%)

1 (20,0%)

Pt

I

0 (0%)

6 (100,0%)

0%

0%

II

0 (0%)

6 (37,5%)

9 (56,3%)

1 (6,3%)

48

0,0001

III

3 (42,9%)

2 (28,6%)

2 (28,6%)

0 (0%)

IV

0 (0%)

15 (78,9%)

4 (21,1%)

0 (0%)

Mitotic rate per mm2

0

0 (0%)

9 (75,0%)

2 (16,7%)

1 (8,3%)

>1

3 (10,0%)

16 (53,3%)

11(36,7%)

0 (0%)

42

0,133

TILs

Absent

1 (5,9%)

10 (58,8%)

5 (29,4%)

1 (5,9%)

Nonbrisk

0 (0%)

13 (61,9%)

8 (38,1%)

0 (0%)

48

0,339

Brisk

2 (20,0%)

6 (60,0%)

2 (20,0%)

0 (0%)

Ulceration

Present

1 (5,9%)

11 (64,7%)

5 (29,4%)

0 (0%)

48

1

Absent

2 (6,5%)

18 (58,1%)

10(32,3%)

1 (3,2%)

Predominant cell type

Epithelioid

1 (3,2%)

22 (71,0%)

8 (25,8%)

0 (0%)

Spindle

2 (20,0%)

2 (20,0%)

5 (50,0%)

1 (10,0%)

48

0,045

Other

0 (0%)

5 (71,4%)

2 (28,6%)

0 (0%)

Melanoma Type

Superficial spreading melanoma

0 (0%)

7 (77,8%)

2 (22,2%)

0 (0%)

Nodular melanoma

3 (12,5%)

12 (50,0%)

9 (37,5%)

0 (0%)

48

0,286

Acrolentiginous melanoma

0 (0%)

6 (75,0%)

1 (12,5%)

1 (12,5%)

Lentigo maligna melanoma

0 (0%)

4 (57,1%)

3 (42,9%)

0 (0%)

Sentinel lymph node

negative

3 (11,1%)

16 (59,3%)

7 (25,9%)

1 (3,7%)

micrometastases

0 (0%)

4 (80,0%)

1 (20,0%)

0 (0%)

48

0,431

subcapsular

0 (0%)

7 (77,8%)

2 (22,2%)

0 (0%)

diffuse

0 (0%)

2 (28,6%)

5 (71,4%)

0 (0%)

Nevus

8(80,0%)

2(20,0%)

0(0%)

0(0%)

10

Primary melanoma

3(6,3%)

29(60,4%)

15(31,3%)

1(2,1%)

48

Metastasis

1

2 (33,3%)

2 (33,3%)

2 (33,3%)

0 (0%)

2

0 (0%)

10 (83,3%)

1 (8,3%)

1 (8,3%)

48

0,013

3

1 (3,3%)

17 (56,7%)

12(40,0%)

0 (0%)